TRAKYA BÖLGESİNDE GÖRÜLEN RETİNA VEN KÖK TIKANIKLIKLARINDA KLİNİK SEYİR VE PROGNOZ

Öz

AMAÇ: Retina ven kök tıkanıklığı (RVKT) olan olgularda genel demografik özelliklerin, sonuç görme keskinliğini etkileyen lokal ve genel etmenlerin belirlenmesi ve tedavi seçeneklerinin karşılaştırılması amaçlanmıştır.
GEREÇ VE YÖNTEM: Çalışmaya 1983 - 2013 yılları arasında retina ven kök tıkanıklığı tanısı almış 294 hastanın 310 gözü dahil edildi. Hastaların dosya kayıtlarından; demografik veriler, eşlik eden sistemik ve oküler hastalıklar, oftalmolojik muayene bulguları, takip süresi ve uygulanan tedaviler kayıt edildi.
BULGULAR: Hastaların yaş ortalaması 63.61 ± 12.8 idi. 136’sı kadın, 158’i erkek idi. 139 hastada sadece sağ, 139 hastada sadece sol, 16 hastada ise her iki gözde hastalık tespit edildi. Hastaların ortalama takip süreleri 38.56 ± 49.45 ay idi. %61.9’unda hipertansiyon, %23.46’sında diyabetus mellitus ve %15.98’inde hiperlipidemi saptandı. %65.8’inin iskemik, %34.2’sinin ise iskemik olmayan tipte olduğu belirlendi. Tıkanma öncesinde veya sonrasında oral antiagreagan ve antikoagulan kullanımının ya da tıkanma sonrası pentoksifilin tedavisinin sonuç görmeyi etkilemediği belirlendi.
SONUÇ: RVKT ile birliktelik gösteren risk faktörlerinin tespiti ve tedavi edilmesi, hastalığın oluşum ve ilerleyişini engellemede önemli bir yaklaşımdır. Hastalığın kontrolü ve hastaların yaşam kalitelerinin arttırılması için yeni tedavi yöntemlerine ve önleyici mekanizmaların geliştirilmesine ihtiyaç duyulmaktadır.

Anahtar Kelimeler

• Retina ven kök tıkanıklığı
• Risk faktörleri
• Görme keskinliği

CLINICAL COURSE AND PROGNOSIS OF RETINAL VEIN OCCLUSIONS SEEN IN THRACIAN REGION

Öz

OBJECTIVE: It was aimed to determine the general demographic characteristics, local and general factors affecting the final visual acuity and to compare the treatment options in patients with central retinal vein root occlusion (RVCT).
MATERIAL AND METHODS: A total of 310 eyes of 294 patients had been diagnosed with central retinal vein occlusion between 1983 - 2013 were included in the study. Demographic data, accompanying systemic and ocular diseases, ophthalmic examination findings, follow-up period, and treatments were recorded from the file records of patients.
RESULTS: The mean age of the patients was 63.61 ± 12.8 years. Of the patients, 136 were female and 158 were male. Disease was detected only in the right eye in 139 patients, in the left eye in 139 patients, and in both eyes in 16 patients. The mean follow-up period of the patients was 38.56 ± 49.45 months. 61.9% of patients had hypertension, 23.46% had diabetes mellitus and 15.98% had hyperlipidemia. It was determined that 65.8% of patients were ischemic and 34.2% were non-ischemic type. It was determined that oral antiagreagans and anticoagulants usage before or after the occlusion and pentoxifylline therapy after the occlusion does not affect the final visual acuities.
CONCLUSIONS: Detection and treatment of risk factors with RVCT, is an important approach in preventing the formation and progression of the disease. There is a need to develop new treatment methods and preventive modalities in order to control the disease and increase the quality of life of the patients.

Anahtar Kelimeler

• Retinal vein occlusion
• Risk factors
• Visual acuity

Kaynakça

1. 1. Bearelly S, Fekrat S. Controversy in the management of retinal venous occlusive disease. Int Ophthalmol Clin. 2004;44(4):85-102.
2. 2. Ozmen MC, Ozdek Ş. Retina ven tıkanıklıklarına bağlı gelişen makula ödeminde güncel tedavi yöntemleri. Retina-Vitreus. 2008;16:1-8.
3. 3. David R, Zangwill L, Badarna M, et al. Epidemiology of retinal vein occlusion and its association with glaucoma and increase intraocular pressure. Ophthalmologica. 1988;197:69-74.
4. 4. Hayreh SS. Classification of central retinal vein occlusion. Ophthatmotogy. 1983;90:458-74.
5. 5. Hayreh SS. Retinal vein occlusion. Indian J Ophthalmol. 1994;42:109-32.
6. 6. Prisco D, Marcucci R. Retinal vein thrombosis: Risk factors, pathogenesis and therapeutic approach. Pathophysiol Haemost Thromb. 2002;32(5-6):308-11.
7. 7. Topbaş S. Santral retinal ven tıkanıklığı güncel tedavisi. Retina-Vitreus. 2004;12:239-43.
8. 8. Tao Y, Hou J, Jiang YR, et al. Intravitreal bevacizumab vs triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Eye (Lond). 2010;24(5):810-5.

9. 9. Wu WC, Cheng KC, Wu HJ. Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular edema due to central retinal vein occlusion. Eye (Lond). 2009;23(12):2215-22.
10. 10. Gregori NZ, Rattan GH, Rosenfeld PJ, et al. Safety and efficacy of intravitreal bevacizumab (avastin) for the management of branch and hemiretinal vein occlusion. Retina. 2009;29(7):913-25.
11. 11. Fish GE. Intravitreous bevacizumab in the treatment of macular edema from branch retinal vein occlusion and hemisphere retinal vein occlusion. Trans Am Ophthalmol Soc. 2008;106:276-300.
12. 12. Appiah AP, Trempe CL. Risk factors associated with branch vs. central retinal vein occlusion. Ann Ophthalmol. 1989;21(4):153-5,157.
13. 13. Duker JS. Retina and Vitreous. In: Yanoff MY, Duker JS (Eds). Ophthalmology. Saint Louis: Mosby Company.1998; 771-82.
14. 14. Madsen PH. Experiences in surgical treatment of haemorrhagic glaucoma. Acta Ophthalmol. 1973;120:88-95.
15. 15. Brown GC, Magargal LE, Schachat A, et al. Neovascular glaucoma: etiologic consideration. Ophthalmology. 1984;91(4):315-20.
16. 16. Baumal CR, Brown GC. Treatment of central retinal vein occlusion. Ophthalmic Surg Lasers. 1997;28(7):590-600.
17. 17. Markowitz SN, Morin JD. Endothelium in primary angle-closure glaucoma. Am J Ophthalmol. 1984;98(1):103-4.
18. 18. Ozdemir H, Karacorlu M, Karacorlu SA. Serous macular detachment in central retinal vein occlusion. Retina. 2005;25(5):561-6.
19. 19. McGrath MA, Wechsler F, Hunyor AB, et al. Systemic factors contributory to retinal vein occlusion. Arch Intern Med. 1978;138(2):216-20.
20. 20. Lee JY, Yoon YH, Kim HK, et al. Baseline characteristics and risk factors of retinal vein occlusion: a study by the Korean RVO Study Group. J Korean Med Sci. 2013;28(1):136- 44.
21. 21. Klein R, Klein BE, Moss SE, et al. The epidemiology of retinal vein occlusion: The Beaver Dam Eye Study. Trans Am Ophthalmol So. 2000;98:133-41.
22. 22. Hayreh SS, Zimmerman B, McCarthy MJ, et al. Systemic diseases associated with various types of retinal vein occlusion. Am J Ophthalmol. 2001;131(1):61-77.
23. 23. Hayreh SS, Rojas P, Podhajsky P, et al. Ocular neovascularization with retinal vascular occlusion-III. Incidence of ocular neovascularization with retinal vein occlusion. Ophthalmology. 1983;90(5):488-506.
24. 24. Zhang HR, Xia YJ. Risk factors and visual prognosis of 407 patients with retinal vein occlusion. Zhonghua Yan Ke Za Zhi. 1991;27(5):271-4.
25. 25. Lang GE, Handel A. Clinical and fluorescein angiography changes in patients with central retinal vein occlusion. A unicenter study of 125 patients. Klin Monatsbl Augenheilkd. 1992;201(5):302-8.
26. 26. Hayreh SS, Klugman MR, Beri M, et al. Differentiation of ischemic from non-ischemic central retinal vein occlusion during the early acute phase. Graefes Arch Clin Exp Ophthalmol. 1990;228(3):201-17.
27. 27. Servais GE, Thompson HS, Hayreh SS. Relative afferent pupillary defect in central retinal vein occlusion. Ophthalmology. 1986;93(3):301-3.
28. 28. The Central Vein Occlusion Study Group. Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol. 1997;115(4):486-91.
29. 29. Zegarra H, Gutman FA, Conforto J. The natural course of central retinal vein occlusion. Ophthalmology. 1979;86(11):1931-42.
30. 30. Sedney SC. Photocoagulation in Retinal Vein Occlusion [dissertation]. In: JunkW (Ed.). The Hague: The Netherlands. 1976:21-7.
31. 31. Hayreh SS, Podhajsky PA, Zimmerman MB. Central and hemicentral retinal vein occlusion: role of anti-platelet aggregation agents and anticoagulants. Ophthalmology. 2011;118(8):1603-11.